文献速递头颈外科

老年头颈癌患者的治疗耐受性与结局

Treatment tolerability and outcomes in elderly patients with head and neck cancer.
PubMed 文献 · Head Neck · 2020-12-08

年龄和合并症与毒性无关,治疗中断与体重下降和较差总生存相关,但与疾病特异性生存和局部区域控制无关。

要点

  • 年龄和合并症与治疗毒性无关(P ≥ .05)
  • 治疗中断与体重下降(P = .042)和较差总生存(P < .001)相关
  • 治疗中断与疾病特异性生存(P = .45)和局部区域控制(P = .21)无关

核心结论

  • 治疗中断与体重下降和较差总生存相关,但与疾病相关结局无关,提示中断可能是其他问题的替代指标。

主要发现

  • 年龄和合并症与毒性不相关(P ≥ .05)。
  • 经历治疗中断的患者体重下降更显著(P = .042)且总生存更差(P < .001)。
  • 治疗中断与疾病特异性生存(P = .45)和局部区域控制(P = .21)无显著关联。

临床怎么用

  • 老年头颈癌患者治疗中断应警惕体重下降和潜在其他问题,需密切监测和干预。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The number of elderly patients with head and neck squamous cell carcinoma (HNSCC) continues to grow. Management of this cohort remains poorly defined. We investigated treatment tolerability and clinical outcomes in this underrepresented population. METHODS: We identified patients aged ≥70 with nonrecurrent, nonmetastatic HNSCC treated curatively from 2007-2018 and analyzed clinical covariates. RESULTS: Two hundred and twenty patients with a median age of 75 (interquartile range:72-80) were identified. Age and comorbidities were not correlated with toxicity (P ≥ .05). Patients who experienced a treatment interruption had significantly greater weight loss (P = .042) and worse overall survival (OS) (P < .001), but not worse disease-specific survival (P = .45), or locoregional control (P = .21). CONCLUSIONS: Treatment interruptions were associated with weight loss and worse OS, but not disease related outcomes, suggesting an interruption in the elderly may be a surrogate for another issue. In sum, our data should guide clinical trial design to benefit this growing, neglected cohort.

来源:Head Neck,查看原文。版权归原作者所有。

引用

  1. Dickstein DR, Egerman M, Monrose E, et al. Treatment tolerability and outcomes in elderly patients with head and neck cancer. Head Neck. 2020. PMID: 33615611. doi:10.1002/hed.26548

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。